RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
China Healthcare Channel

subscribe to China Healthcare newsletter
Healthcare : China Healthcare

   EMAIL   |   PRINT
GenoMed CEO Invited to Speak at World DNA Day in China

Apr 29, 2005 - 8:08:00 PM
"It's an extraordinary honor to be invited to such a prestigious gathering of Nobel prize-winners and other scientific luminaries. Genomics is fulfilling the hope that thousands of physician-scientists have entertained for several thousand years: to find the source of human diseases so we can stop them. It's like finding the headwaters of a river in order to dam it."

 
[RxPG] GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, was invited to speak yesterday at World DNA and Genome Day in Dalian, China (www.dnaday.com) on "Genomics and Cardiovascular Disease."

Said Dr. Moskowitz, "It's an extraordinary honor to be invited to such a prestigious gathering of Nobel prize-winners and other scientific luminaries. Genomics is fulfilling the hope that thousands of physician-scientists have entertained for several thousand years: to find the source of human diseases so we can stop them. It's like finding the headwaters of a river in order to dam it."

Dr. Moskowitz continued, "Overactivity of angiotensin I-converting enzyme, known as 'ACE,' seems to be the cause of most diseases of aging, including cardiovascular disease and cancer, the two main causes of death in the U.S. Inhibitors of ACE have been used for over 25 years, although not in the doses pioneered by GenoMed. Actual patient outcomes over the next decade or two will prove whether we've found the Fountain of Youth or not. This hypothesis comes at a good time for Baby Boomers like me."



Publication: GenoMed, Inc.
On the web: www.genomed.com 

Advertise in this space for $10 per month. Contact us today.


Related China Healthcare News
Mental health check-up not to be compulsory in China
Chinese woman cuts open her belly to save surgery cost
Chinese mayor sacked over baby food scandal
A woman changes lepers' world in China
China issues bird flu alert
Ageing China faces rural healthcare vacuum
30 percent increase in HIV cases in China: report
GenoMed CEO Invited to Speak at World DNA Day in China

Subscribe to China Healthcare Newsletter

Enter your email address:


 Additional information about the news article

About GenoMed

GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. DM (Disease Management) is the only industry in healthcare which profits by lowering healthcare costs. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether ACE is the major aging gene; (b) whether we will have sufficient financing to conduct our research and development; and (c) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)